NO MONEY OR OTHER CONSIDERATION IS BEING SOLICITED, AND IF SENT IN RESPONSE, WILL NOT BE ACCEPTED. NO OFFER TO BUY THE SECURITIES CAN BE ACCEPTED AND NO PART OF THE PURCHASE PRICE CAN BE RECEIVED UNTIL THE OFFERING STATEMENT IS FILED AND ONLY THROUGH AN INTERMEDIARY’S PLATFORM. AN INDICATION OF INTEREST INVOLVES NO OBLIGATION OR COMMITMENT OF ANY KIND. "RESERVING" SECURITIES IS SIMPLY AN INDICATION OF INTEREST.
GET A PIECE OF VITA IMAGING
Invest in Medical Tech Company Detecting Skin Cancer In Seconds
Why Investors Are Talking About Vita Imaging
The Problem & Our Solution
5.4 million people are treated for skin cancer yearly.
However, current methods for detecting skin cancer are costly, inefficient, and subjective.
That’s why Vita Imaging created AURA: the first-of-its kind, non-invasive raman spectroscopy device that can identify benign and malignant lesions in less than 2 seconds. The AURA is currently advancing toward FDA market clearance and preparing for commercial launch after successful testing in comprehensive clinical studies.
The AURA product is pre-FDA approval and is not yet available in the market.
The AURA is so easy it can be operated in just three, non-invasive steps, meaning it can quickly be deployed in any dermatological clinic or healthcare facility.
Power up the AURA Imaging Device
Scan the Affected Area Using the Light Probe Instant Result ( < 1.5sec)
Review Display for Diagnosis & Recommended Next Steps
AURA Development –Past to Present
To-date, the AURA™ has been tested in comprehensive clinical studies – including the largest known study using Raman technology for skin cancer detection – and has successfully passed all product performance and safety tests. Therefore, we believe that AURA™ has strong potential to exceed FDA benchmarks, ideally paving the way for full clearance and commercialization as a Class 3 medical device.
Sir CV raman’s original system (1928)
Rapid raman system built at the bc cancer agency (2002)
Beta test version
First generation commercial product (2012)
VITA IMAGING’S AURA (2023)
The AURA product is pre-FDA approval and is not yet available in the market.
This would make the AURA the first approved device of its kind on the market, paving the way for mass adoption in the market.
AURA Development –Past to Present
To-date, the AURA™ has been tested in comprehensive clinical studies – including the largest known study using Raman technology for skin cancer detection – and has successfully passed all product performance and safety tests. Therefore, we believe that AURA™ has strong potential to exceed FDA benchmarks, ideally paving the way for full clearance and commercialization as a Class 3 medical device.
Sir CV raman’s original system (1928)
Rapid raman system built at the bc cancer agency (2002)
Beta test version
First generation commercial product (2012)
VITA IMAGING’S AURA (2023)
The AURA product is pre-FDA approval and is not yet available in the market.
This would make the AURA the first approved device of its kind on the market, paving the way for mass adoption in the market.
There is No Competition
A high-quality skin cancer detection device requires two properties to be successful:
While other medical device companies tout their skin cancer diagnostic devices, no product currently on the market matches the AURA’s sensitivity, specificity and testing time in a non-invasive device.
Why Invest
A Strong Business Model
Vita Imaging has a quality business model that will provide the company with solid cash flow from both device sales, recurring revenue, and potential future business opportunities.
Vita Imaging Roadmap
We already have exciting plans for the coming years, including:
Featured On
Our Experienced Team is Unmatched
Thinh Tran • CEO & Chairman
Mr. Tran was the Founder, CEO, & Chairman of V-Silicon, a leader in the Smart TV market delivering best in class picture and audio quality. He was previously the Founder, Chairman, & CEO of Sigma Designs since its inception in 1982 which he built from a humble start-up a publicly traded NASDAQ company, at one point was valued at two billion dollars in 2007, before leaving in 2018…
Maria Victoria ReadeCOO
Ms. Reade has 25+ years of executive leadership and consulting experience including: Executive Director, MCO Operations & MSO at Scripps Clinic & Green Hospital La Jolla; VP, Medical Management at HMO Pacificare, Healthcare/IT Consultant at Deloitte, TMI, Pharma & Medtech…
Dzung Kim Tran WrightCFO
Ms. Wright is the Chief Financial Officer of Vita Imaging, Inc. She has over 30 years of experience in the financial industry, holding senior financial positions at multiple publicly traded and startup companies over a wide range of industries such as medical, telecommunications, device technology, digital arts, mobile devices, and internet technology…
Invest in a Company That’s Doing Good For the World, And Your Portfolio
Invest in a Company That’s Doing Good For the World, And Your Portfolio
Join us and help us create a new standard in medical diagnostics.
Join us and help us create a new standard in medical diagnostics.
The AURA product is pre-FDA approval and is not yet available in the market.